Company
3 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a REMS (Risk Evaluation and Mitigation Strategy) for an existing acetaminophen–codeine combination; this is a regulatory action, not a clinical evidence report, and does not contain trial data or efficacy claims.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for a REMS (Risk Evaluation and Mitigation Strategy) modification to an existing hydrocodone-ibuprofen combination product; this is a regulatory action, not a clinical evidence report.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of an opioid formulation under REMS requirements; this is a regulatory action, not a clinical evidence evaluation.